Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has promoted Thomas Englese to chief commercial officer, effective immediately, as the company intensifies efforts to commercialize its recently approved fibromyalgia treatment, TONMYA. Englese, who previously served as executive vice president of commercial operations since September 2024, will now lead all commercial functions, including sales, marketing, market access, and commercial operations for TONMYA and the company’s migraine products, Zembrace SymTouch and Tosymra.
The promotion comes at a pivotal time for Tonix, which is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) and immunology treatments. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) represents a significant milestone as the first new treatment for fibromyalgia in more than 15 years. The company’s CNS commercial infrastructure is designed to support its marketed products, and Englese’s leadership is expected to be instrumental in expanding access and growing the patient and prescriber base for TONMYA.
President and CEO Seth Lederman highlighted Englese’s role in building Tonix’s commercial organization and launching TONMYA. Englese echoed this sentiment, stating that the company is focused on broadening the TONMYA launch and increasing sales. This strategic emphasis on commercial execution is critical as Tonix seeks to establish a strong foothold in the fibromyalgia market, which has seen limited innovation for over a decade.
Beyond TONMYA, Tonix is leveraging the science behind the drug to explore its potential in other CNS indications. The company is conducting Phase 2 clinical trials to evaluate TONMYA in major depressive disorder and acute stress disorder. Additionally, Tonix’s CNS pipeline includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder. The company is also advancing immunology programs, including TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection.
This promotion signals Tonix’s commitment to building a robust commercial infrastructure to support its growing portfolio. With Englese at the helm of commercial operations, the company aims to maximize TONMYA’s market potential while preparing for future product launches. The success of TONMYA is particularly important for Tonix, as it represents a new revenue stream and validates the company’s ability to bring innovative treatments to market.
For investors, the promotion underscores Tonix’s strategic direction and operational focus. The company’s newsroom provides updates on recent developments, and the full press release regarding this promotion is available at https://ibn.fm/uzRyl. As Tonix continues to execute its commercial strategy, stakeholders will be watching closely to see how TONMYA performs in the market and how the company’s pipeline progresses.
Tonix Pharmaceuticals is dedicated to addressing areas of high unmet medical need in CNS and immunology. With a commercial-stage platform and a promising pipeline, the company is positioning itself for growth. The appointment of Thomas Englese as chief commercial officer is a key step in that journey, ensuring that Tonix has the leadership in place to drive commercial success.
